Gyre Therapeutics Plunges 15.88% on Public Offering

Gyre Therapeutics' stock price plummeted by 15.88% during pre-market trading on May 26, 2025, marking a significant decline for the biotech company.

Gyre Therapeutics recently announced a public offering of common stock, raising approximately $20.0 million. This move is part of the company's strategy to secure additional funding for its ongoing clinical trials, particularly the Phase 2 MASH-related trials in the United States. The underwriters have an option to purchase up to an additional 333,333 shares, which could further bolster the company's financial position.

This stock offering comes at a time when Gyre Therapeutics is focusing on expanding its clinical pipeline and enhancing its financial runway. The company's decision to raise capital through a public offering reflects its commitment to advancing its therapeutic programs and potentially bringing new treatments to market.